Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.

ABSTARCT: The original article [1] contains two errors in Table 2.

Correction

The original article [1] contains two errors in Table 2:

Table 2

Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib

Clinical outcomes	With adverse events (n = 150)	Without adverse events (n = 119)	Unadjusted analysis		Multi-adjusted analysisa
			HR/ORb (95% CI)	P valuec	HR/OR (95% CI)	P valued
Median overall survival (IQR), days	169 (96–255)	103 (58–201)	0.67 (0.51,0.88)	0.0039	0.64 (0.48,0.84)	0.001
Median progression-free survival (IQR), days	86.5 (57–150)	62 (41–121)	0.75 (0.58,0.98)	0.0309	0.69 (0.53,0.91)	0.007
Disease control rate, n (%)	82 (54.67)	39 (32.77)	2.47 (1.46,4.21)	< 0.001	2.67 (1.59,4.47)	< 0.001
Objective response rate, n (%)	11 (7.33)	6 (5.04)	1.49 (0.49.5.06)	0.443	1.42 (0.50,4.01)	0.505

Adverse events are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment

HR hazard ratio, OR odds ratio, IQR interquartile range

aAdjusted for sex, every 10-year increase in age, number of metastatic sites and ECOG PS

bHR for overall survival and progression survival; OR for disease control rate and objective response rate

cP values calculated from log-rank test for overall survival and progression survival, and chi-square test for disease control rate and objective response rate

dP values calculated from Cox regression for overall survival and progression survival, and logistic regression for disease control rate and objective response rate

The data values in the rows ‘Disease control rate’ and ‘Objective response rate’ and the columns ‘With adverse events’ and ‘Without adverse events’ have mistakenly been interchanged between columns; the values ‘39 (32.77)’ and ‘6 (5.04)’ should be swapped with the values ‘82 (54.67)’ and ‘11 (7.33)’ respectively.

The value for the row ‘Median progression-free survival (IQR)’ for the ‘HR/OR’ sub-column should be 0.69, not 0.79.

As such, the table displayed ahead shows the correct presentation of Table 2 and should be considered instead.